XML 47 R37.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

LICENSE AGREEMENTS (Details) - USD ($) $ in Millions | 1 Months Ended | 9 Months Ended
--- | --- | ---
Feb. 28, 2023 | Jan. 31, 2022 | Dec. 31, 2020 | Aug. 31, 2017 | Mar. 31, 2024
XOMA (US) LLC | Xoma License Agreement | Upon Clinical and Regulatory Milestones | Maximum |  |  |  |  |
License Agreements |  |  |  |  |
Maximum amount of milestone events |  | $ 35.0 |  |  |
XOMA (US) LLC | Xoma License Agreement | After Clinical and Regulatory Milestones | Maximum |  |  |  |  |
License Agreements |  |  |  |  |
Maximum amount of milestone events |  | 185.0 |  |  |
XOMA (US) LLC | Phase 2 Clinical Trial RZ358 | Xoma License Agreement |  |  |  |  |
License Agreements |  |  |  |  |
Milestone closing payment |  | $ 2.0 |  |  |
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon First Dosing Of The First Patient |  |  |  |  |
License Agreements |  |  |  |  |
Milestone closing payment |  |  |  |  | $ 5.0
ActiveSite Pharmaceuticals, Inc |  |  |  |  |
License Agreements |  |  |  |  |
Royalties percentage |  |  |  | 2.00% |
ActiveSite Pharmaceuticals, Inc | Development And License Agreement |  |  |  |  |
License Agreements |  |  |  |  |
Milestone closing payment |  |  | $ 1.0 |  |
ActiveSite Pharmaceuticals, Inc | Development And License Agreement | Plan | Maximum |  |  |  |  |
License Agreements |  |  |  |  |
Maximum amount of milestone events |  |  |  | $ 46.5 |
ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement |  |  |  |  |
License Agreements |  |  |  |  |
Milestone closing payment | $ 3.0 |  |  |  |
ActiveSite Pharmaceuticals, Inc | Phase 3 Clinical Trial RZ 402 | Development And License Agreement | Scenario, Upon First Dosing Of The First Patient |  |  |  |  |
License Agreements |  |  |  |  |
Milestone closing payment |  |  |  | $ 5.0 |

X
- Definition Represents the percentage of royalties. + References No definition available. + Details
Name: | rzlt_DevelopmentAndLicenseAgreementRoyaltiesPercentage
Namespace Prefix: | rzlt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of milestone event which need to occur for making specific range of milestone payment. + References No definition available. + Details
Name: | rzlt_MaximumAmountOfMilestoneEvents
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of milestone payment made during the period. + References No definition available. + Details
Name: | rzlt_MilestoneClosingPayment
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=rzlt_ScenarioAfterClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase2ClinicalTrialRz358Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz358Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=rzlt_ScenarioUponFirstDosingOfFirstPatientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rzlt_ActivesitePharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rzlt_DevelopmentAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase2ClinicalTrialRz402Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz402Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |